^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CCNA2 (Cyclin A2)

    i
    Other names: CCNA2, CCN1, CCNA, Cyclin A2
    2d
    Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers. (PubMed, J Med Chem)
    Here we describe the optimization of this series for drug-like properties and oral bioavailability, resulting in the discovery of a lead compound, which demonstrates tumor regression in CDX models of SCLC via oral dosing. We are currently evaluating Cyclin A/B inhibition in a Phase 1 clinical trial.
    Journal
    |
    CCNA2 (Cyclin A2)
    3d
    Functional effects of EpCAM N-glycosylation in MDA-MB-468 breast cancer cells. (PubMed, Sci Rep)
    Similarly, there was no effect of unglycosylated EpCAM on cell viability, migration, invasion, or homotypic adhesion, although we did observe slight increases in homotypic cell-cell adhesion in EpCAM overexpressing cells. These findings show that N-glycosylation has a significant impact on stability and subcellular localization of EpCAM, but not on several critical breast cancer cell properties important for cancer progression and metastasis in human triple-negative MDA-MB-468 breast cancer cells.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • EPCAM (Epithelial cell adhesion molecule) • CCNA2 (Cyclin A2)
    7d
    A comprehensive analysis of palmitoylation related genes in lung adenocarcinoma. (PubMed, Discov Oncol)
    Five key genes (TPPP, FAAH, CACNB1, GLOD5, CCNA2) were validated in local LUAD samples. The PM model serves as a clinically relevant tool for prognosis and treatment prediction in LUAD, highlighting the potential role of palmitoylation in tumor progression and therapy stratification.
    Journal • IO biomarker
    |
    CCNA2 (Cyclin A2)
    8d
    Kojic acid inhibits melanoma progression by targeting the MYC-CCNA2/KPNA2 axis. (PubMed, Gene)
    Single-cell analysis further localized this axis to a proliferative mitotic subpopulation, promoting melanoma progression. These findings uncover a previously unrecognized mechanism by which KA inhibits melanoma growth and suggest that targeting the MYC-CCNA2/KPNA2 pathway may provide a therapeutic strategy for melanoma.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCNA2 (Cyclin A2) • KPNA2 (Karyopherin Subunit Alpha 2)
    15d
    Pharmacological Potential of Chalepensin from Ruta chalepensis L.: Acute Toxicity and In Vivo Antitumor Activity in the L5178Y-R Murine Model. (PubMed, J Ethnopharmacol)
    Chalepensin demonstrates promising antitumor activity against L5178Y-R murine lymphoma, along with a favorable acute toxicity profile. These findings support its potential for further preclinical development and warrant additional studies to elucidate its molecular mechanisms and long-term safety.
    Preclinical • Journal
    |
    CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2)
    |
    vincristine
    21d
    Mining in Endometrial Cancer Based on the TCGA Database and Constructing Prognostic Models. (PubMed, J Vis Exp)
    Nicotinamide metabolism was found to be significantly linked with EC progression. This study offers new perceptions into the role of nicotinamide metabolism in EC and suggests possible avenues for treatment advancements.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AURKA (Aurora kinase A) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • FOXM1 (Forkhead Box M1) • CDK1 (Cyclin-dependent kinase 1) • CDK3 (Cyclin Dependent Kinase 3)
    21d
    Synthesis or preparation, physicochemical characterization, and H460 cell inhibition of selenium nanoparticles stabilized by Marsdenia tenacissima residue polysaccharide. (PubMed, Int J Biol Macromol)
    WB and RT-qPCR analysis further confirmed this dual mechanism, revealing downregulation of key cell cycle regulators (Cyclin A/D and CDK2/4) and activation of the mitochondrial apoptotic pathway, characterized by an increased Bax/Bcl-2 ratio and caspase-3 activation. This study not only presents a sustainable strategy for utilizing Marsdenia tenacissimaresidue but also highlights the promise of polysaccharide-based nanodrugs in cancer therapy.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2)
    22d
    Pro-Tumorigenic Roles of Cyclin Dependent Kinase 2 and its Associated Cyclins in Cholangiocarcinoma Progression under High Glucose Condition. (PubMed, Arch Med Res)
    CCA cells with upregulated CDK2 and its cyclin partners in HG were more sensitive to tagtociclib at a higher dose. Cyclin E and cyclin A also regulated CCA metastasis by controlling epithelial-mesenchymal transition. Targeting CDK2 and its associated cyclins in CCA cells demonstrated therapeutic potential that requires further translational and clinical verification.
    Journal
    |
    CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2)
    |
    tegtociclib (PF-07104091)
    23d
    Exploring the mechanism and therapeutic potential of BUB1 in regulating esophageal cancer progression based on 5-FU target prediction. (PubMed, Discov Oncol)
    This study revealed the important role of BUB1, one of the potential targets of 5-FU, in the development of esophageal cancer. Through bioinformatics analysis and experimental validation, we found that the high expression of BUB1 in esophageal cancer tissues was closely related to the biological properties of the tumor. the regulation of cell cycle by BUB1 and its role in the invasion and migration ability of the cells marked its potential as a new target for the treatment of esophageal cancer.
    Journal
    |
    CCNA2 (Cyclin A2) • CDK1 (Cyclin-dependent kinase 1) • MYBL2 (MYB Proto-Oncogene Like 2) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase)
    |
    5-fluorouracil
    23d
    The miR-29b Byproduct MIRTX Shows Superior Anti-tumor Activity, Compared to miR-29b-3p, in Pancreatic Cancer Cells. (PubMed, Anticancer Res)
    MIRTX is a potential therapeutic miRNA in pancreatic cancer cells.
    Journal
    |
    CCNA2 (Cyclin A2) • CCNB2 (Cyclin B2)
    24d
    Integrative Bioinformatics and Experimental Validation Establish CCNB1 as a Potential Biomarker for Diagnosis and Prognosis in Colorectal Cancer. (PubMed, Curr Issues Mol Biol)
    In vitro, CCNB1 knockdown triggered cell cycle arrest, thereby suppressing the proliferation of colorectal cancer cells. This study validated CCNB1 as a dual-purpose biomarker for CRC diagnosis and favorable prognosis, highlighting its potential utility in clinical management.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • CDCA3 (Cell Division Cycle Associated 3) • CCNA2 (Cyclin A2) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDC20 (Cell Division Cycle 20) • KIF11 (Kinesin Family Member 11) • MCM4 (Minichromosome Maintenance Complex Component 4) • CCNB1 (Cyclin B1) • CDK3 (Cyclin Dependent Kinase 3) • CEP55 (Centrosomal Protein 55) • CKS2 (CDC28 Protein Kinase Regulatory Subunit 2) • CRYAB (Crystallin Alpha B) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MMP3 (Matrix metallopeptidase 3) • TPM2 (Tropomyosin 2) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    26d
    Herba Patriniae Component Linarin Induces Cell Cycle Arrest and Senescence in Non-Small-Cell Lung Cancer Associated with Cyclin A2 Downregulation. (PubMed, Pharmaceuticals (Basel))
    These effects are associated with the downregulation of key cell cycle regulators, including CCNA2/B1 and CHEK1. Together, these findings highlight the potential of Linarin as a promising therapeutic option for NSCLC.
    Journal
    |
    TP53 (Tumor protein P53) • CHEK2 (Checkpoint kinase 2) • CHEK1 (Checkpoint kinase 1) • CCNA2 (Cyclin A2) • CDK1 (Cyclin-dependent kinase 1)
    |
    TP53 wild-type